全球镰状细胞病治疗市场 – 行业趋势和 2028 年预测

市场分析和见解：全球镰状细胞病治疗市场

预计镰状细胞病治疗市场在 2021 年至 2028 年的预测期内将以 16.4% 的速度增长。Data Bridge Market Research 关于镰状细胞病治疗市场的报告提供了有关预计在整个预测期内普遍存在的各种因素的分析和见解，同时提供了它们对市场增长的影响。移民人数的增加正在加速镰状细胞病治疗市场的增长。

镰状细胞病 (SCD) 是一种遗传性血液疾病，其特征是因β-珠蛋白基因突变而导致红细胞 (RBC) 僵硬、异常、呈镰状。该病的严重程度因人而异。

预计在预测期内推动镰状细胞病治疗市场增长的主要因素是移民人口的增加。此外，预计医疗服务的增强和对镰状细胞病治疗的投资将进一步推动镰状细胞病治疗市场的增长。另一方面，预计有效治疗方案的缺乏将进一步阻碍镰状细胞病治疗市场在预测期内的增长。

In addition, the inaccessibility of drugs in the rural areas will further provide potential opportunities for the growth of the sickle cell disease treatment market in the coming years. However, the rise in the price of treatment and decrease in the healthcare expenses in a few countries might further challenge the growth of the sickle cell disease treatment market in the near future.

The sickle cell disease treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the sickle cell disease treatment market scenario, contact Data bridge market research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Global Sickle Cell Disease Treatment Market Scope and Market Size

The sickle cell disease treatment market is segmented on the basis of type, symptoms type, complications type, treatments type, medications type, route of administration, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, hemoglobin Sβ0 thalassemia, hemoglobin Sβ+ thalassemia, hemoglobin SC and others.
• On the basis of symptoms type, the sickle cell disease treatment market is segmented into anemia, episodes of pain, frequent infections and others.
• On the basis of complications type, the sickle cell disease treatment market is segmented into stroke, acute chest syndrome, pulmonary hypertension, organ damage and others.
• On the basis of treatments type, the sickle cell disease treatment market is segmented into medication, blood transfusion, bone marrow transplantation and others.
• On the basis of medications type, the sickle cell disease treatment market is segmented into antibiotics, pain-relieving medications, hydroxyurea, others.
• On the basis of route of administration, the sickle cell disease treatment market is segmented into oral, injectable and others.
• On the basis of end users, the sickle cell disease treatment market is segmented into hospitals, homecare, specialty clinics, others.
• On the basis of distribution channel, the sickle cell disease treatment market is segmented into hospital pharmacy, online pharmacy, retail pharmacy, others.

Sickle Cell Disease Treatment Market Country Level Analysis

The sickle cell disease treatment market is analyzed, and market size information is provided by country, type, Symptoms Type, complications type, treatments type, medications type, route of administration, end users and distribution channel as referenced above.

The countries covered in the sickle cell disease treatment market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA).

North America dominates the sickle cell disease treatment market due to the possible launch of pipeline drugs. Furthermore, the rise in the acceptance of novel therapeutics and the increase in the population will further boost the growth of the sickle cell disease treatment market in the region during the forecast period. Europe is projected to observe significant amount of growth in the sickle cell disease treatment market due to the suitable reimbursement policies. Moreover, the rise in the number of births with sickle cell disease is further anticipated to propel the growth of the sickle cell disease treatment market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The sickle cell disease treatment market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Sickle Cell Disease Treatment Market Share Analysis

镰状细胞病治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用主导地位、技术生命线曲线。以上提供的数据点仅与公司对镰状细胞病治疗市场的关注有关。

镰状细胞病治疗市场报告中涉及的主要参与者包括 Addmedica、Emmaus Medical, Inc.、Global Blood Therapeutics Inc.、bluebird bio, Inc.、Pfizer Inc.、Novartis AG、Bristol-Myers Squibb Company、Endo Pharmaceuticals Inc.、Teva Pharmaceutical Industries Ltd.、Sun Pharmaceutical Industries Ltd.、Mayne Pharma Group Limited、CELGENE CORPORATION、Ironwood Pharmaceuticals, Inc.、Amgen Inc.、Zydus Cadila、Silver Lake Research Corporation、Ionis Pharmaceuticals, Inc.、Vertex Pharmaceuticals Incorporated、Alkem Labs 和 Purdue Pharma LP 以及其他国内和全球参与者。再生医学市场份额数据分别针对全球、北美、南美、欧洲、亚太地区 (APAC) 和中东及非洲 (MEA) 提供。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

SKU-50046